Previous 10 | Next 10 |
Summary Viatris' gross margin reached its highest level since its inception in the fourth quarter of 2020, despite rising raw material and labor costs. On February 27, 2023, Viatris management will publish financial results for the 4th quarter of 2022. Viatris' operating income for ...
If you’re looking for penny stocks to buy, you’re not alone. One of the main attractions to this niche in the stock market today is the potential for quick gains. Not only that, but in many cases, these gains can be extreme. On an almost daily basis, you’re sure to see at lea...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2022 financial results on Thursday March 2, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. East...
Summary As a leader in various therapeutic areas, the company's total revenue was $7,042 million in the third quarter of 2022, up 12.5% quarter-on-quarter. Gilead will be required to make royalties of 3% on future sales of Biktarvy and bictegravir-containing medicines up to the 4th quar...
Summary The inability to efficiently market new drugs might put significant pressure on AMRX's margins, which can lead to a substantial stock price correction. As the business has been expanding its drug portfolio, in the upcoming years, profitability might improve significantly. I ...
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with this event. For further details see: Amneal Pharmaceuticals (AMRX) presents at 41st Annual J.P. Morgan Healthcare Conference - Slideshow
Generic and specialty drugmaker Amneal Pharmaceuticals ( NYSE: AMRX ) reiterated its previously issued financial guidance for the year ending December 31, 2022, on Tuesday as part of its presentation at the ongoing JPMorgan Healthcare Conference. The detailed outlook indicates $2.15B ...
Amneal Pharmaceuticals ( NYSE: AMRX ) has signed a long-term license agreement with Orion Corporation to commercialize a number of complex generic products. Under the partnership agreement, Orion is Amneal’s exclusive partner to bring its portfolio of complex generic progra...
- Long-term collaboration to bring Amneal generic products to market in Europe, Australia, and New Zealand Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has signed a long-term license agreement with Orion Corporati...
- 8 new product launches in Q4 closes out another successful year of innovation - First approval of a large volume bag product signals further expansion of injectables business Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) ...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...